Companies Compete to Create DMT Therapies

Lucid News has published an article covering the landscape of companies working to create DMT Therapies. Once considered fringe medicine and the domain of maverick clinical researchers, innovators in the psychedelics field are now poised to make a significant contribution to the mental health landscape worldwide. 

The article covers some of the cutting-edge research being done by Small Pharma, Atai Life Sciences, Algernon Pharmaceuticals, MindMed, Psilera, and Entheon. Almost all of the competing companies in this space are in the pre-clinical trials stage of DMT-assisted therapies.

Small Pharma is both the world’s first regulated clinical trial for DMT-assisted therapy in major depressive disorder as well as the only company that has entered Phase IIa of their trials.

Small Pharma note that their “proprietary intravenous formulation of DMT was very well tolerated in individuals with no previous experience of psychedelics.”


About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: